

Abstract

The present invention relates to a liposome based formulation of erythropoietin comprising:

- 5 (a) an effective amount of an erythropoietin;
- (b) a lipidic phase comprising:
 - (i) lecithin or hydrogenated lecithin;
 - (ii) optionally, a charged electropositive or electronegative lipid compound; and
 - 10 (iii) cholesterol or a derivative thereof selected from cholesterol esters, polyethylene glycol derivatives of cholesterol (PEG-cholesterols), and organic acid derivatives of cholesterols; and
- (c) a phosphate buffer.

15 The liposome based parenteral dosage form of the invention is prepared by means of an ethanol injection technique. The composition avoids the need for use of human serum albumin and exhibits superior stability.